Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab plus PARP inhibitor in HRD-positive advanced solid tumors
ChiCTR2100053410Phase 4Not yet recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zimberelimab in Nonhematologic neoplasms, sponsored by Xuzhou Central Hospital. Primary endpoint: Objective response rate. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
zimberelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100053410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053410.